# Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins: Phase 1 study closed enrollment, 31 enrolled (High Risk Cancer, Pancreatic Cancer)

**Score:** 30/100

| Field | Value |
|---|---|
| Sponsor | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
| Sponsor type | Academic and hospital |
| Study | Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer |
| NCT ID | NCT05013216 |
| Phase | Phase 1 |
| Status | active not recruiting |
| Conditions | High Risk Cancer; Pancreatic Cancer |
| Intervention types | drug |
| Target enrollment | 31 |
| Site countries | United States |
| Posted | 2021-08-19 |
| Planned start | 2022-04-11 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-06 |
| Last update posted | 2026-10-06 |

## Why this score
- Enrollment closed: data management, monitoring and closeout ahead.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT05013216). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.